Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

NCT01265576 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC

Interventions

DRUG: Sorafenib
DRUG: VT-122 (propranolol plus etodolac)
DRUG: Placebo

Sponsor

Vicus Therapeutics